Importance of continuous support from various healthcare professionals in the decision-making process about disclosure of PGPV/GPV following cancer genomic profiling tests: a case report and our approach

DOI
  • Ueno Sayaka
    Section of Translational Research, Hyogo Cancer Center Division of Clinical Genetics, Hyogo Cancer Center
  • Toji Sawako
    Clinical Center for Cancer Genomics and Clinical Research, Hyogo Cancer Center
  • Urakawa Yusaku
    Division of Medical Oncology, Kobe City Medical Center General Hospital
  • Minami Tomoya
    Division of Clinical Laboratory, Hyogo Cancer Center
  • Sugawara Hiromi
    Division of Clinical Genetics, Hyogo Cancer Center
  • Itagaki Ai
    Division of Clinical Genetics, Hyogo Cancer Center
  • Hinoshita Saki
    Division of Nursing, Hyogo Cancer Center
  • Matsumoto Koji
    Division of Clinical Genetics, Hyogo Cancer Center Division of Medical Oncology, Hyogo Cancer Center
  • Sudo Tamotsu
    Section of Translational Research, Hyogo Cancer Center Clinical Center for Cancer Genomics and Clinical Research, Hyogo Cancer Center
  • Tamura Kazuo
    Division of Clinical Genetics, Hyogo Cancer Center

Bibliographic Information

Other Title
  • 多職種による継続的サポートが，がん遺伝子パネル検査における生殖細胞系列の遺伝情報開示の意思決定に重要であった症例：当院での取り組みについて

Search this article

Abstract

<p>　Cancer genomic profiling （CGP） test may reveal presumed germline pathogenic variant / germline pathogenic variant （PGPV/GPV）. Therefore, patients should decide in advance whether or not they want to learn about their PGPV/GPVs. We report a case in which the patient changed the mind 7 months after the CGP test. A 67-year-old female patient with lung cancer underwent CGP testing because of disease progression after primary treatment with cytotoxic anti-cancer drugs. Although she initially did not want to learn her PGPVs and did not change her mind when she heard the results of the CGP test, she changed her mind and requested disclosure of PGPVs 7 months later. When she heard the result of CGP test, she was full of anxiety about her next treatment and complained of hyposomnia. Mental support by a professional nurse and follow-up by a by a cancer genome medical coordinator （CGMC） enabled her to discuss with her family how to deal with PGPVs. A confirmatory test verified the germline pathogenic variant. The patient's daughters were followed up at the genetic clinic. In this case, the collaboration among nurses, doctors, and the genetic medicine department coordinated by the CGMC strongly supported the patient's decision-making process. In this report, we present our approach in establishing collaboration among various healthcare professionals.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top